Home
Conditions
Stage I Multiple Myeloma

Clinical trial condition

Stage I Multiple Myeloma

Explore clinical trials studying Stage I Multiple Myeloma. Study availability and eligibility vary by location and protocol.

34 public trials 0 recruiting studies

Refine in advanced search Browse all conditions

Stage I Multiple Myeloma trial results

Completed

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

NCT01706666

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Johns Hopkins University Baltimore, Maryland, United States

Washington University School of Medicine St Louis, Missouri, United States

Baylor Medical Center Garland, Texas, United States

View Trial Details

Completed

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

NCT01273766

Conditions: Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +206 more
Locations: Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States

View Trial Details

Completed

Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer

NCT01053494

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Amyloidosis, +170 more
Locations: Wake Forest University Health Sciences Winston-Salem, North Carolina, United States

View Trial Details

Completed

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

NCT01057225

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic Rochester, Minnesota, United States

Medical University of South Carolina Charleston, South Carolina, United States

View Trial Details

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

NCT00006244

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients

NCT01653106

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Digestive System Diseases, +22 more
Locations: Ohio State University Medical Center Columbus, Ohio, United States

View Trial Details

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

NCT00182663

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

NCT00112593

Conditions: AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, +281 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

NCT00795769

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adnexal Diseases, Adult Acute Lymphoblastic Leukemia in Remission, +202 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

NCT00619684

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Stage I Multiple Myeloma

Stage I Multiple Myeloma trial results

Related conditions